trial

Hippocampus DBS in Treatment-resistant Schizophrenia

NCTId NCT05694000
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 6 (estimated)
Sponsored by Shanghai Mental Health Center
Primary completion 2024-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
6 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2022-11-01
Primary completion
2024-12
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
On-StimulationOff-Stimulation

Sponsors

Shanghai Mental Health CenterLead Sponsor
Huashan HospitalCollaborator

Investigators

1
Dengtang Liu, MDPrincipal Investigator

Sites

1 total
Shanghai, China

Facts & assertions

4 sourced
Enrollment
6
Phase
NA
Primary Completion Date
2024-12
Status
UNKNOWN
relationships
The graph out of here
drug
On-Stimulation
drug
Off-Stimulation
drug
lead_sponsor
Shanghai Mental Health Center
company
collaborator
Huashan Hospital
company
indication
Schizophrenia, Treatment-Resistant
indication
Treatment-resistant Schizophrenia
indication
investigator
Dengtang Liu, MD
person